Article Text

PDF
Could toll-like receptors provide a missing link in chronic inflammation in rheumatoid arthritis? Lessons from a study on human rheumatoid tissue
  1. Sandra M Sacre1,*,
  2. Stefan K Drexler1,*,
  3. Evangelos Andreakos2,
  4. Marc Feldmann1,
  5. Fionula M Brennan1,
  6. Brian M J Foxwell1
  1. 1
    Kennedy Institute of Rheumatology Division, Faculty of Medicine, Imperial College of Science, Technology and Medicine, London, UK
  2. 2
    Foundation for Biomedical Research of the Academy of Athens, Center for Immunology and Transplantations, Athens, Greece
  1. Brian Foxwell, Kennedy Institute of Rheumatology Division, Imperial College London, 1 Aspenlea Road, Hammersmith, London W6 8LH, UK; b.foxwell{at}imperial.ac.uk

Abstract

In the last decade the development of a number of biological therapies has revolutionised the treatment of rheumatic diseases. The first and most widely used of these approaches, tumour necrosis factor (TNF) blockade (infliximab, entanercept, adalimumab), has now been administered to over a million patients. However, the success of these biological therapies has also highlighted their limitations. None of these treatments has shown a 100% patient response; normally responses are in the 50–70% range. As proteins, these drugs cannot be given orally and they are expensive to produce, a cost ultimately borne by the patient/health provider that can seriously limit the availability of these drugs. Lastly, these treatments, whether involving the systemic neutralisation of a cytokine (eg, TNF or IL6 receptor blockade (tocilizumab)), the ablation of a B cell population (anti-CD20, rituximab), or the potential disruption of important cellular interactions as with CTLA4-Ig (abatacept), can cause major perturbations of the immune system, the long-term effects of which are still unclear. At present, treatments such as TNF blockade can result in an increased infectious risk and the reactivation of tuberculosis can be a major issue in certain populations. As with all therapies, there is an increasing large refractory population over time. Therefore, despite the undoubted success of these therapies, there is room for improvement. Although it might be too much to expect any new treatment to affect a “cure” (all the current biological therapies require repeated administrations), there are definite gains to be made in terms of cost, oral bioavailability and a more selective interference with the immune–inflammatory response.

Statistics from Altmetric.com

Footnotes

  • Competing interests: None declared.

  • * These authors contributed equally to the work.

  • Abbreviations:
    MMP
    matrix metalloproteinases
    PAMPs
    pathogen-associated molecular patterns
    RA
    rheumatoid arthritis
    SLE
    systemic lupus erythematosus
    TIR
    toll/interleukin 1 receptor
    TLR
    toll-like receptor
    TNF
    tumour necrosis factor

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.